Evaluating Critical Asset Safeguards for Pharmaceutical Manufacturers
Learn how we provided a critical asset safeguard evaluation to support technical and operational excellence for a pharmaceutical company's manufacturing assets.
Pharmaceutical and Biotechnology companies create products that generate billions of dollars in annual sales. As product demand and manufacturing outputs increase for these products, so do the demands for trouble free manufacturing equipment, performance and reliability requirements. One central issue for these companies' supply chains is the lack of an effective risk management process for readily identifying the potential for equipment performance issues or breakdowns. The absence of such a process creates a major imperative for these companies.
The Asset Performance Optimization service line of ABS Group launched an initiative to address risk and equipment reliability issues that may affect the products manufactured by a global pharmaceutical company. A risk management solution was developed to standardize an approach to addressing specific products across the company's multiple facilities.
- Improve the safeguard robustness of critical manufacturing assets/equipment
- Identify and rank the criticality of each asset supporting the product line using Asset Criticality Ranking (ACR) tools
- Develop a risk management strategy that uses What If Analysis
Identify and rank the assets to be reviewed and locate the equipment on a boundary diagram
Apply ACR scope and What If Analysis to evaluate safeguard robustness
Analyze the Heat Map summary
Prioritize the risk management action items